Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042456 | 1.00 | DRD2 (0.60) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL4744663 | 0.93 | DRD2 (0.66) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL8041665 | 0.86 | DRD2 (0.61) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL8041667 | 0.86 | DRD2 (0.61) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL8041643 | 0.84 | DRD2 (0.59) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL8042461 | 0.84 | DRD2 (0.59) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL8041645 | 0.84 | DRD2 (0.59) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL8041668 | 0.83 | DRD2 (0.57) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL9128978 | 0.80 | PDE10A (0.44) | DRD2MEN1KMT2A | |
| SCHEMBL8042432 | 0.79 | DRD2 (0.66) | DRD2MEN1KMT2AATMGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133275-A | ALPHA 1 ADRENORECEPTOR ANTAGONISTS; TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER UROLOGICAL DISEASES E.G., BLADDER OUTLET OBSTRUCTION), NEUROGENIC BLADDER AND GYNECOLOGICAL SYNDROMES, E.G., DYSMENORRHEA; UTERINE MUSCLE RELAXANTS | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |